Elyssa Ott

701 total citations
14 papers, 491 citations indexed

About

Elyssa Ott is a scholar working on Immunology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Elyssa Ott has authored 14 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 6 papers in Genetics and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Elyssa Ott's work include Inflammatory Bowel Disease (6 papers), Psoriasis: Treatment and Pathogenesis (3 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Elyssa Ott is often cited by papers focused on Inflammatory Bowel Disease (6 papers), Psoriasis: Treatment and Pathogenesis (3 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Elyssa Ott collaborates with scholars based in United States, Canada and United Kingdom. Elyssa Ott's co-authors include Chandrasekhar Udata, O. Vesterqvist, Lisa Hickey, Michael E. Burczynski, Arie Katz, Meng Xu, Subrata Ghosh, Christopher Gasink, C Gasink and Lianne S. Gensler and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and Inflammatory Bowel Diseases.

In The Last Decade

Elyssa Ott

13 papers receiving 478 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elyssa Ott United States 9 199 164 118 101 88 14 491
Nora Ratcliffe United States 10 166 0.8× 52 0.3× 58 0.5× 122 1.2× 77 0.9× 21 443
Remco van Dijk Netherlands 11 61 0.3× 152 0.9× 80 0.7× 110 1.1× 146 1.7× 19 564
Sumie Hiramatsu Japan 13 173 0.9× 61 0.4× 29 0.2× 65 0.6× 100 1.1× 37 477
John T. Bickel United States 11 103 0.5× 93 0.6× 46 0.4× 44 0.4× 84 1.0× 25 414
Eitan Giat Israel 7 178 0.9× 64 0.4× 30 0.3× 52 0.5× 210 2.4× 14 487
D Breborowicz Poland 10 41 0.2× 105 0.6× 138 1.2× 47 0.5× 131 1.5× 27 430
Jan-Hendrik Riedel Germany 9 500 2.5× 83 0.5× 32 0.3× 33 0.3× 71 0.8× 13 661
Ekaterini Politi Greece 11 103 0.5× 106 0.6× 24 0.2× 49 0.5× 137 1.6× 29 487
Yichuan Xia United States 4 637 3.2× 142 0.9× 165 1.4× 34 0.3× 63 0.7× 6 892
Bong Ryoul Oh United States 13 88 0.4× 79 0.5× 181 1.5× 49 0.5× 463 5.3× 23 798

Countries citing papers authored by Elyssa Ott

Since Specialization
Citations

This map shows the geographic impact of Elyssa Ott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elyssa Ott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elyssa Ott more than expected).

Fields of papers citing papers by Elyssa Ott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elyssa Ott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elyssa Ott. The network helps show where Elyssa Ott may publish in the future.

Co-authorship network of co-authors of Elyssa Ott

This figure shows the co-authorship network connecting the top 25 collaborators of Elyssa Ott. A scholar is included among the top collaborators of Elyssa Ott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elyssa Ott. Elyssa Ott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Ghosh, Subrata, Brian G. Feagan, Elyssa Ott, et al.. (2024). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis. Journal of Crohn s and Colitis. 18(7). 1091–1101. 17 indexed citations
2.
Ghosh, Subrata, Elyssa Ott, C Gasink, et al.. (2023). P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications. Journal of Crohn s and Colitis. 17(Supplement_1). i681–i682. 1 indexed citations
3.
Abraham, Bincy, Elyssa Ott, Lindsay Miller, et al.. (2022). Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis. Crohn s & Colitis 360. 4(3). otac025–otac025. 11 indexed citations
4.
Long, Millie D., Silvio Danese, Elyssa Ott, et al.. (2021). S930 Safety of Ustekinumab Across Approved Adult Indications: Pooled Safety Analysis in Crohn’s Disease, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis Through up to 5 Years. The American Journal of Gastroenterology. 116(1). S441–S441.
5.
Abreu, María T., Elyssa Ott, Christopher Gasink, et al.. (2021). S885 Safety of Ustekinumab in Older IBD Patients (≥60 Years): Pooled Safety Analysis Through 5 Years in CD and 2 Years in UC and All Approved Indications. The American Journal of Gastroenterology. 116(1). S416–S416. 1 indexed citations
6.
Sandborn, William J., Brian G. Feagan, Elyssa Ott, et al.. (2021). 129 SAFETY OF USTEKINUMAB IN IBD: POOLED SAFETY ANALYSIS THROUGH 5 YEARS IN CD AND 2 YEARS IN UC. Gastroenterology. 160(6). S–35. 1 indexed citations
7.
Ghosh, Subrata, Elyssa Ott, Christopher Gasink, Miao Ye, & Jean‐Frédéric Colombel. (2021). 131 SAFETY OF USTEKINUMAB IN IBD: A COMPREHENSIVE ANALYSIS OF MAJOR CARDIOVASCULAR EVENTS (MACE) THROUGH 5 YEARS IN CD AND 2 YEARS IN UC. Gastroenterology. 160(6). S–37. 3 indexed citations
8.
Sandborn, William J., Brian G. Feagan, Silvio Danese, et al.. (2020). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases. 27(7). 994–1007. 77 indexed citations
9.
Ghosh, Subrata, Lianne S. Gensler, Zijiang Yang, et al.. (2019). Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs. Drug Safety. 42(6). 751–768. 80 indexed citations
10.
Ferris, Laura K., Elyssa Ott, Jingzhi Jiang, et al.. (2019). Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. Journal of Dermatological Treatment. 31(2). 152–159. 42 indexed citations
11.
Scherl, Ellen, et al.. (2018). A109 PREGNANCY OUTCOMES IN WOMEN EXPOSED TO USTEKINUMAB IN THE CROHN’S DISEASE CLINICAL DEVELOPMENT PROGRAM. Journal of the Canadian Association of Gastroenterology. 1(suppl_2). 166–166. 12 indexed citations
12.
Reich, Kristian, Kim Papp, C.E.M. Griffiths, et al.. (2012). An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.. PubMed. 11(3). 300–12. 62 indexed citations
13.
Katz, Arie, Chandrasekhar Udata, Elyssa Ott, et al.. (2009). Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR‐623, a Novel Liver X‐Receptor Agonist, in Healthy Participants. The Journal of Clinical Pharmacology. 49(6). 643–649. 151 indexed citations
14.
Ott, Elyssa. (2005). A Randomized Trial Assessing Dorzolamide in Patients With Glaucoma Who Are Younger Than 6 Years. Archives of Ophthalmology. 123(9). 1177–1177. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nora Ratcliffe Breakdown of academic impact, for papers by Remco van Dijk Breakdown of academic impact, for papers by Sumie Hiramatsu Breakdown of academic impact, for papers by John T. Bickel Breakdown of academic impact, for papers by Eitan Giat Breakdown of academic impact, for papers by D Breborowicz Breakdown of academic impact, for papers by Jan-Hendrik Riedel Breakdown of academic impact, for papers by Ekaterini Politi Breakdown of academic impact, for papers by Yichuan Xia Breakdown of academic impact, for papers by Bong Ryoul Oh
Rankless by CCL
2026